Investing.com -- Silexion Therapeutics Corp (NASDAQ:SLXN) stock rose 5.9% Tuesday after the company announced successful completion of toxicology studies for its cancer therapy SIL204, confirming no systemic organ toxicity in two species.
The positive toxicology results keep the clinical-stage biotechnology company on track to initiate a Phase 2/3 clinical trial for locally advanced pancreatic cancer in the second quarter of 2026. Silexion is now preparing regulatory submissions to health authorities in Israel and Germany.
SIL204 is a next-generation RNA silencing therapy designed to target mutated KRAS oncogenes, which drive aggressive cancers. The company reported that preclinical studies demonstrated significant inhibition of cancer cell growth across various KRAS mutated cell lines and showed anti-tumor activity in pancreatic cancer following systemic administration.
"Results from the toxicology studies have cleared us to maintain our planned timelines to initiate SIL204’s Phase 2/3 clinical trial in pancreatic cancer," said Ilan Hadar, Chairman and Chief Executive Officer of Silexion. "We have recently secured our CRO partner for the trial and continue to prepare regulatory submissions to both Israel’s Ministry of Health and Germany’s Health Authority."
The company’s approach combines both intratumoral and systemic administration of the therapy, which it believes could improve survival rates for pancreatic cancer patients while maintaining quality of life.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
